Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | ILK | Q13418 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670354 | 0.85 | HDAC6 (0.72) | HDAC6AURKAAURKBHDAC3HDAC1 | |
| SCHEMBL30923250 | 0.85 | F7 (0.56) | HDAC6AURKAJAK2AURKBHDAC3 | |
| SCHEMBL31141640 | 0.83 | HDAC6 (0.73) | HDAC6AURKAJAK2AURKBHDAC3 | |
| SCHEMBL30033167 | 0.81 | SYK (0.54) | HDAC6AURKAAURKBHDAC3HDAC1 | |
| SCHEMBL3698385 | 0.81 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14607583 | 0.79 | HCAR3 (0.76) | AURKAJAK2AURKBHCAR3IRAK4 | |
| SCHEMBL18713280 | 0.79 | HDAC6 (0.68) | HDAC6AURKAJAK2AURKBHDAC3 | |
| SCHEMBL29818028 | 0.79 | HDAC1 (0.60) | HDAC6AURKAAURKBHDAC3HDAC1 | |
| SCHEMBL30923236 | 0.78 | RAB9A (0.47) | HDAC6JAK2MAPK10VNN1 | |
| SCHEMBL17005800 | 0.78 | HDAC3 (0.59) | HDAC6HDAC3HDAC1HDAC2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699553-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | CNR2, CNR1, P2RY2 | HDAC6 2003/4885AURKA 3476/4885JAK2 345/4885 |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | HDAC6 515/4885AURKA 1234/4885JAK2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.